The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Telmisartan, Ramipril, or Both in Patients at High Risk of Vascular Events
Abstract
To the Editor: The investigators of the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial (ONTARGET) (April 10 issue)1 report that telmisartan is equivalent to ramipril in patients with vascular disease or high-risk diabetes. However, the primary composite end point of death from cardiovascular causes, myocardial infarction, stroke, or hospitalization for heart failure was not lower in the combination-therapy group than in the group receiving ramipril alone, even though blood-pressure levels in the combination-therapy group were 2.4/1.4 mm Hg lower than those in the ramipril group throughout the study period. Still more disturbing was a trend in the combination-therapy group toward even more deaths from cardiovascular and noncardiovascular causes than in the ramipril or telmisartan group (deaths from cardiovascular causes, 620 vs. 603 and 598, respectively; deaths from noncardiovascular causes, 445 vs. 411 and 391, respectively). Given that the number of patients with hyperkalemia was much higher in the combination-therapy group than in the ramipril or telmisartan group (480 vs. 283 and 287, respectively), as was the number of patients with hypotensive symptoms (406 vs. 149 and 229, respectively), we wonder whether a specific cause of death (i.e., sudden death or death from arrhythmia) can be identified in the combination-therapy group. Data from such an analysis should be provided.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Telmisartan, ramipril, or both in patients at high risk for vascular events
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801317 · Cited by 3,502
Pfeffer, M. A., McMurray, J. J. V., Velazquez, E. J., Rouleau, J.-L., Køber, L., Maggioni, A. P., Solomon, S. D., Swedberg, K., Van de Werf, F., White, H., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa032292 · Cited by 2,471
Research works printed but not linked: 8
- 10.1056/NEJMe0801925 · DOI
- Matchar DB, 2008, Ann Intern Med, 148, 16, 10.7326/0003-4819-148-1-200801010-00189 · DOI · Paper page
- 10.1016/S0140-6736(97)01187-2 · DOI · Paper page
- 10.1016/S0140-6736(00)02213-3 · DOI · Paper page
- 10.1016/S0140-6736(02)09895-1 · DOI · Paper page
- 10.1056/NEJMoa032292 · DOI · Paper page
- 10.1056/NEJMe0801925 · DOI
- 10.1056/NEJMoa0801317 · DOI · Paper page
Cited by
Mancia, G., Kreutz, R., Brunström, M., Burnier, M., Grassi, G., Januszewicz, A., Muiesan, M. L., Tsioufis, K., Agabiti-Rosei, E., Algharably, E. A. E., et al. (2023) · Journal of Hypertension · doi:10.1097/hjh.0000000000003480 · Cited by 3,473
Li, N.-C., Lee, A., Whitmer, R. A., Kivipelto, M., Lawler, E., Kazis, L. E., & Wolozin, B. (2010) · BMJ · doi:10.1136/bmj.b5465 · Cited by 486
Roffi, M., Patrono, C., Collet, J.-P., Mueller, C., Valgimigli, M., Andreotti, F., Bax, J. J., Borger, M. A., Brotons, C., Chew, D. P., et al. (2015) · Kardiologia Polska · doi:10.5603/kp.2015.0243 · Cited by 458
Drafts, B. C., Twomley, K. M., D'Agostino, R., Lawrence, J., Avis, N., Ellis, L. R., Thohan, V., Jordan, J., Melin, S. A., Torti, F. M., et al. (2013) · JACC: Cardiovascular Imaging · doi:10.1016/j.jcmg.2012.11.017 · Cited by 391
Slagman, M. C. J., Waanders, F., Hemmelder, M. H., Woittiez, A.-J., Janssen, W. M. T., Lambers Heerspink, H. J., Navis, G., Laverman, G. D., & for the HONEST (HOlland NEphrology STudy) Group (2011) · BMJ · doi:10.1136/bmj.d4366 · Cited by 286
Metadata
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2008-07-24
- Volume
- 359
- Issue
- 4
- Pages
- 426-427
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W47715785
- Cited by
- 175
- References
- 2
- FWCI
- 12.32
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Telmisartan, Ramipril, or Both in Patients at High Risk of Vascular Events. https://app.cochat.ai/papers/10.1056/nejmc081065
- The paper
- Telmisartan, Ramipril, or Both in Patients at High Risk of Vascular Events. (2008). New England Journal of Medicine. https://doi.org/10.1056/nejmc081065
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.